BNT153 / BioNTech - LARVOL DELTA

BNT152-01C: Dose Escalation Trial of BNT152+153 in Patients With Cancer (clinicaltrials.gov) - P1 | N=86 | Completed | Sponsor: BioNTech SE | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Oncology • Solid Tumor

BNT152-01C: Dose Escalation Trial of BNT152+153 in Patients With Cancer (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: BioNTech SE | Recruiting ➔ Active, not recruiting | N=170 ➔ 86

Enrollment change • Enrollment closed • Oncology • Solid Tumor

Dose Escalation Trial of BNT152+153 in Patients With Cancer (clinicaltrials.gov) - P1 | N=170 | Recruiting | Sponsor: BioNTech SE | N=112 ➔ 170 | Trial completion date: Oct 2023 ➔ Sep 2025 | Trial primary completion date: Oct 2023 ➔ Sep 2025

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Dose Escalation Trial of BNT152+153 in Patients With Cancer (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: BioNTech SE | N=60 ➔ 112 | Trial completion date: Jul 2023 ➔ Oct 2023 | Trial primary completion date: Jul 2023 ➔ Oct 2023

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Dose Escalation Trial of BNT152+153 in Patients With Cancer (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: BioNTech SE; Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

BioNTech Announces Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) - “BNT122…First patient dosing in a randomized Phase 2 trial in circulating tumor DNA positive, surgically resected Stage 2 (high risk)/Stage 3 colorectal cancer is expected in the first half of 2021…BNT152+153 – In February, the U.S. FDA approved the IND for a Phase 1 trial for BNT152+153. We plan to start a Phase 1 trial for BNT152 (encoding IL-7) plus BNT153 (encoding IL-2) in multiple solid tumors in the first half of 2021.”

New P1 trial • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Dose Escalation Trial of BNT152+153 in Patients With Cancer (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: BioNTech SE

Clinical • New P1 trial • Oncology • Solid Tumor

BioNTech announces full year 2019 financial results and corporate update (GlobeNewswire) - "BNT151 – Initiation of a Phase 1 trial in multiple solid tumors (optimized IL-2) is now expected in 1H 2021; BNT152+153 – Initiation of a Phase 1 trial in multiple solid tumors is now expected in 1H 2021."

New P1 trial